A detailed history of Concord Wealth Partners transactions in Novo Nordisk A S stock. As of the latest transaction made, Concord Wealth Partners holds 80 shares of NVO stock, worth $8,476. This represents 0.0% of its overall portfolio holdings.

Number of Shares
80
Previous 19 321.05%
Holding current value
$8,476
Previous $2,000 350.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

BUY
$119.07 - $145.42 $7,263 - $8,870
61 Added 321.05%
80 $9,000
Q2 2024

Jul 31, 2024

BUY
$122.71 - $146.91 $2,331 - $2,791
19 New
19 $2,000
Q1 2024

Apr 30, 2024

SELL
$102.11 - $135.92 $34,513 - $45,940
-338 Closed
0 $0
Q4 2023

Apr 30, 2024

SELL
$87.78 - $105.45 $7,724 - $9,279
-88 Reduced 20.66%
338 $34,000
Q4 2023

Feb 05, 2024

SELL
$87.78 - $105.45 $7,724 - $9,279
-88 Reduced 20.66%
338 $34,000
Q3 2023

Apr 30, 2024

BUY
$90.94 - $199.54 $8,002 - $17,559
88 Added 26.04%
426 $38,000
Q3 2023

Oct 25, 2023

BUY
$90.94 - $199.54 $23,371 - $51,281
257 Added 152.07%
426 $38,000
Q4 2022

Jan 27, 2023

BUY
$102.55 - $135.33 $17,330 - $22,870
169 New
169 $22,000
Q2 2022

Aug 04, 2022

SELL
$103.24 - $121.81 $19,202 - $22,656
-186 Reduced 47.57%
205 $23,000
Q1 2022

Apr 20, 2022

SELL
$93.1 - $112.54 $372 - $450
-4 Reduced 1.01%
391 $43,000
Q4 2021

Jan 21, 2022

BUY
$95.88 - $117.08 $35,763 - $43,670
373 Added 1695.45%
395 $44,000
Q3 2021

Nov 09, 2021

SELL
$84.42 - $106.62 $11,059 - $13,967
-131 Reduced 85.62%
22 $2,000
Q2 2021

Jul 29, 2021

BUY
$67.66 - $84.76 $10,351 - $12,968
153 New
153 $13,000

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $239B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Concord Wealth Partners Portfolio

Follow Concord Wealth Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concord Wealth Partners, based on Form 13F filings with the SEC.

News

Stay updated on Concord Wealth Partners with notifications on news.